An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC) as well as looking at the effects that lazertinib and JNJ-61186372 have when taken together. Lazertinib is taken orally and JNJ-61186372 is an intravenous drug. Lazertinib (YH25448) belongs to a class of drugs called EGFR tyrosine kinase inhibitors, which helps slow the growth or stop the cancer cells. JNJ-61186372 is an antibody. Antibodies are proteins that bind to certain targets. In test tubes and animals, JNJ-61186372 binds to two different types of targets that can be found on cancer cells.
This study is closed
Catherine Shu, MD
|Are you at least 18 years old?
|Do you have non small cell lung cancer?
|Do you have symptomatic brain metastases or brain metastases requiring treatment?
|Do you have significant cardiovascular disease?